オルパシラン市場：市場規模、予測、新たな洞察-2032年

オルパシラン（旧AMG 890）は、心血管系イベントのリスク上昇に関連するLp（a）の主要成分であるアポリポ蛋白（a）の体内産生を低下させるように設計された低分子干渉RNAです。

2022年11月、リポ蛋白（a）［Lp（a）］値（＞150nmol/L）が高く、アテローム性動脈硬化性心血管疾患（ASCVD）の既往歴のある成人を対象としたオルパシランの第II相OCEAN（a）-DOSE試験の治療終了データが、米国心臓協会（AHA）学術集会2022のLate-Breaking Scienceセッションで発表され、同時にNew England Journal of Medicine誌に掲載されました。現在第III相試験が実施中で、2027年までにデータが得られる見込みです。

今後数年間で、心筋梗塞の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、オルパシランの優位性に影響を与える可能性のある機会を模索しています。他の心筋梗塞治療薬もオルパシランと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における心筋梗塞治療薬のオルパシラン市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 心筋梗塞におけるオルパシランの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 オルパシラン市場評価

• 心筋梗塞におけるオルパシランの市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国の心筋梗塞治療薬オルパシラン市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Olpasiran, Clinical Trial Description, 2023
• Table 2: Olpasiran, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: Olpasiran Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Olpasiran Market Size in the US, in USD million (2019-2032)
• Table 7: Olpasiran Market Size in Germany, in USD million (2019-2032)
• Table 8: Olpasiran Market Size in France, in USD million (2019-2032)
• Table 9: Olpasiran Market Size in Italy, in USD million (2019-2032)
• Table 10: Olpasiran Market Size in Spain, in USD million (2019-2032)
• Table 11: Olpasiran Market Size in the UK, in USD million (2019-2032)
• Table 12: Olpasiran Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Olpasiran Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Olpasiran Market Size in the United States, USD million (2019-2032)
• Figure 3: Olpasiran Market Size in Germany, USD million (2019-2032)
• Figure 4: Olpasiran Market Size in France, USD million (2019-2032)
• Figure 5: Olpasiran Market Size in Italy, USD million (2019-2032)
• Figure 6: Olpasiran Market Size in Spain, USD million (2019-2032)
• Figure 7: Olpasiran Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Olpasiran Market Size in Japan, USD million (2019-2032)

"Olpasiran Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about olpasiran for myocardial infarction in the seven major markets. A detailed picture of the olpasiran for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the olpasiran for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the olpasiran market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

Olpasiran (formerly AMG 890) is a small interfering RNA designed to lower the body's production of apolipoprotein (a), a key component of Lp (a) that has been associated with an increased risk of cardiovascular events.

In November 2022, the company presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran in adults with elevated lipoprotein (a) [Lp (a)] levels (>150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD) during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2022, and simultaneously published in the New England Journal of Medicine. The company is currently conducting a Phase III trial with data expected by 2027.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the olpasiran description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on olpasiran regulatory milestones and other development activities have been provided in this report.
• The report also highlights the olpasiran research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around olpasiran.
• The report contains forecasted sales of olpasiran for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for olpasiran in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Olpasiran Analytical Perspective by DelveInsight

• In-depth Olpasiran Market Assessment

This report provides a detailed market assessment of olpasiran for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

• Olpasiran Clinical Assessment

The report provides the clinical trials information of olpasiran for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence olpasiran dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to olpasiran and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of olpasiran in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of olpasiran from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the olpasiran in myocardial infarction.

Key Questions:

• What is the product type, route of administration and mechanism of action of olpasiran?
• What is the clinical trial status of the study related to olpasiran in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the olpasiran development?
• What are the key designations that have been granted to olpasiran for myocardial infarction?
• What is the forecasted market scenario of olpasiran for myocardial infarction?
• What are the forecasted sales of olpasiran in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to olpasiran for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

Table of Contents

1. Report Introduction

2. Olpasiran Overview in myocardial infarction

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Olpasiran Market Assessment

• 5.1. Market Outlook of Olpasiran in myocardial infarction
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Olpasiran in the 7MM for myocardial infarction
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Olpasiran in the United States for myocardial infarction
  • 5.3.2. Market Size of Olpasiran in Germany for myocardial infarction
  • 5.3.3. Market Size of Olpasiran in France for myocardial infarction
  • 5.3.4. Market Size of Olpasiran in Italy for myocardial infarction
  • 5.3.5. Market Size of Olpasiran in Spain for myocardial infarction
  • 5.3.6. Market Size of Olpasiran in the United Kingdom for myocardial infarction
  • 5.3.7. Market Size of Olpasiran in Japan for myocardial infarction

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options